Robert L. Barbieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert L. Barbieri has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- A. Heather Eliassen
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
12 shared publications - Allison F. Vitonis
Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
12 shared publications - Amy L. Shafrir
Division of Adolescent/Young Adult Medicine, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
12 shared publications - Daniel William Cramer
Brigham and Women's Hospital, Boston, MA
12 shared publications - Susan E. Hankinson
University of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, Massachusetts
12 shared publications - Tianyi Huang
Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging , Baltimore, MD
12 shared publications
Latest Publications
- Open Access
MicroRNAs Regulated by Pregnancy Target Antiviral and Cancer Immunity Overlapping with the HIV Interactome
Innate immunity predictors of HIV-1 risk and pathogenesis vary with reproductive hormones, pregnancy, and lactation, yet the underlying mechanisms remain unclear. We hypothesized that pregnancy-associated physiological adaptations alter systemic microRNA (miRNA) expression, thereby regulating immunity, pathogenesis and susceptibility to infection. We analyzed 174 serum samples from 88 participants in a longitudinal cohort from Uganda and Zimbabwe across pre-pregnancy (PP), pregnancy (P), and postpartum breastfeeding (BF). Cell-free peripheral blood miRNAs (n = 2083) were profiled using HTG EdgeSeq. Pregnancy-specific miRNAs were identified by intersecting differentially expressed (DE) miRNAs from P vs. PP and P vs. BF comparisons. miRNA targets and pathways were analyzed using miRWalk, Cytoscape/ClueGO, and cytoHubba. Pregnancy was associated with DE miRNAs (29 upregulated and 131 downregulated) targeting 2733 validated genes. Enriched pathways (FDR < 0.05) included adaptive immune response, Hippo Signaling, Cellular Senescence, HSV-1 infection, and two cancer-related pathways. Pregnancy-enriched targets within each pathway overlapped with the HIV–host interactome by 37–88%. Network analysis identified 47 hub genes interacting with 18 HIV-1 proteins, with Tat and gp120 being most connected viral and HLA-A being the most connected host protein. These findings indicate that pregnancy-driven systemic miRNAs target the HIV–host interactome and specifically identify pregnancy-enriched central hub genes involved in cell cycle control, viral immune evasion and replication to be further investigated for their predictive value in HIV acquisition and pathogenesis in longitudinal cohorts and experimental settings.
Open AccessMicroRNAs Regulated by Pregnancy Target Antiviral and Cancer Immunity Overlapping with the HIV Interactome
Innate immunity predictors of HIV-1 risk and pathogenesis vary with reproductive hormones, pregnancy, and lactation, yet the underlying mechanisms remain unclear. We hypothesized that pregnancy-associated physiological adaptations alter systemic microRNA (miRNA) expression, thereby regulating immunity, pathogenesis and susceptibility to infection. We analyzed 174 serum samples from 88 participants in a longitudinal cohort from Uganda and Zimbabwe across pre-pregnancy (PP), pregnancy (P), and postpartum breastfeeding (BF). Cell-free peripheral blood miRNAs (n = 2083) were profiled using HTG EdgeSeq. Pregnancy-specific miRNAs were identified by intersecting differentially expressed (DE) miRNAs from P vs. PP and P vs. BF comparisons. miRNA targets and pathways were analyzed using miRWalk, Cytoscape/ClueGO, and cytoHubba. Pregnancy was associated with DE miRNAs (29 upregulated and 131 downregulated) targeting 2733 validated genes. Enriched pathways (FDR < 0.05) included adaptive immune response, Hippo Signaling, Cellular Senescence, HSV-1 infection, and two cancer-related pathways. Pregnancy-enriched targets within each pathway overlapped with the HIV–host interactome by 37–88%. Network analysis identified 47 hub genes interacting with 18 HIV-1 proteins, with Tat and gp120 being most connected viral and HLA-A being the most connected host protein. These findings indicate that pregnancy-driven systemic miRNAs target the HIV–host interactome and specifically identify pregnancy-enriched central hub genes involved in cell cycle control, viral immune evasion and replication to be further investigated for their predictive value in HIV acquisition and pathogenesis in longitudinal cohorts and experimental settings.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Background:Lifetime ovulatory years (LOY) is estimated by the difference between ages at menopause and menarche subtracting time for events interrupting ovulation. We tested whether LOY influences sex hormone levels in postmenopausal women with at least one intact ovary not using hormones.Methods:Estradiol, estrone, estrone sulfate, total testosterone, dehydroepiandrostendione sulfate, prolactin, and sex hormone binding globulin were measured in 1,976 postmenopausal women from the Nurses’ Health Study. Associations of age, body mass index (BMI), smoking, alcohol use, and other factors on hormones were assessed by t tests and ANOVA. Linear regression was used to assess multivariable adjusted associations between LOY and hormones and trends in hormone levels per 5-year increases in LOY were estimated.Results:Women averaged 61.4 years old, 11.0 years since menopause, with BMI of 25.8 kg/m2. A total of 13.6% had irregular cycles, 17.5% hysterectomy, 6.4% unilateral oophorectomy, and 13.8% were current smokers. Variables associated with one or more hormone levels were included as covariates. Each 5-year increase in LOY was significantly associated with a 5.2% increase in testosterone in women with BMI < 25 kg/m2 and a 7.4% increase in testosterone and 7.3% increase in estradiol in women with above-average BMI.Conclusions:This is the first study to show that greater LOY is associated with higher testosterone in postmenopausal women and higher estradiol in those with elevated BMI, suggesting accumulation of functioning stromal and thecal cells from repeated ovulations and peripheral conversion of testosterone.Impact:A possible explanation for why greater LOY increases risk for breast, endometrial, and ovarian cancer is offered.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Background:Lifetime ovulatory years (LOY) is estimated by the difference between ages at menopause and menarche subtracting time for events interrupting ovulation. We tested whether LOY influences sex hormone levels in postmenopausal women with at least one intact ovary not using hormones.Methods:Estradiol, estrone, estrone sulfate, total testosterone, dehydroepiandrostendione sulfate, prolactin, and sex hormone binding globulin were measured in 1,976 postmenopausal women from the Nurses’ Health Study. Associations of age, body mass index (BMI), smoking, alcohol use, and other factors on hormones were assessed by t tests and ANOVA. Linear regression was used to assess multivariable adjusted associations between LOY and hormones and trends in hormone levels per 5-year increases in LOY were estimated.Results:Women averaged 61.4 years old, 11.0 years since menopause, with BMI of 25.8 kg/m2. A total of 13.6% had irregular cycles, 17.5% hysterectomy, 6.4% unilateral oophorectomy, and 13.8% were current smokers. Variables associated with one or more hormone levels were included as covariates. Each 5-year increase in LOY was significantly associated with a 5.2% increase in testosterone in women with BMI < 25 kg/m2 and a 7.4% increase in testosterone and 7.3% increase in estradiol in women with above-average BMI.Conclusions:This is the first study to show that greater LOY is associated with higher testosterone in postmenopausal women and higher estradiol in those with elevated BMI, suggesting accumulation of functioning stromal and thecal cells from repeated ovulations and peripheral conversion of testosterone.Impact:A possible explanation for why greater LOY increases risk for breast, endometrial, and ovarian cancer is offered.
- Open Access
MICRORNAS REGULATED BY PREGNANCY TARGET THE HIV INTERACTOME
Innate immunity predictors of HIV risk are influenced by reproductive hormone levels, pregnancy, and lactation status. However, the molecular mechanisms underlying these associations remain unclear. MicroRNAs (miRNAs), as post-transcriptional regulators, play key roles in immune regulation and host-virus interactions. We hypothesized that physiological adaptations to pregnancy include the modulation of systemic miRNA expression, which in turn regulates host genes involved in HIV interaction, potentially influencing susceptibility during pregnancy. To test this, we leveraged a large longitudinal cohort from Uganda and Zimbabwe and analyzed 174 serum samples from 88 participants in pre-pregnancy (PP), pregnancy (P), and breastfeeding (BF) states using the HTG EdgeSeq platform. Differentially expressed (DE) miRNAs in pregnancy were identified with false discovery rate (FDR) < 0.1 (29 upregulated and 131 downregulated) by intersecting pairwise comparisons (P vs. PP and P vs. BF). Validated gene targets (2,733) were identified via miRWalk and modular enrichment analysis performed using Cytoscape/ClueGO. Enriched pathways (FDR<0.05) included Adaptive Immune Response, Hippo Signaling, Cellular Senescence, HSV-1 Infection, and two cancer-related pathways. Genes from pregnancy-enriched pathways overlapped with the known HIV-host interactome at the range of 37 to 88%. From this overlap, the Maximal Clique Centrally (MCC) score (cytoHubba) identified 47 unique hub genes acting as essential regulatory nodes of protein-protein interaction (PPI) network. These hub genes were further examined by their expression patterns predicted by DE miRNAs, and explored for their interactions with the HIV interactome, revealing connectivity with 18 HIV proteins - highest with Tat and gp120 - and impact on the HIV replication process. HLA-A was the most connected host gene, followed by BCL2L1, EIF2AK2, PTEN, and CYCS. These findings support the hypothesis that pregnancy-driven systemic miRNAs may shape HIV susceptibility by regulating hub genes with central role in viral evasion of host immunity. GRAPHIC
Open AccessMICRORNAS REGULATED BY PREGNANCY TARGET THE HIV INTERACTOME
Innate immunity predictors of HIV risk are influenced by reproductive hormone levels, pregnancy, and lactation status. However, the molecular mechanisms underlying these associations remain unclear. MicroRNAs (miRNAs), as post-transcriptional regulators, play key roles in immune regulation and host-virus interactions. We hypothesized that physiological adaptations to pregnancy include the modulation of systemic miRNA expression, which in turn regulates host genes involved in HIV interaction, potentially influencing susceptibility during pregnancy. To test this, we leveraged a large longitudinal cohort from Uganda and Zimbabwe and analyzed 174 serum samples from 88 participants in pre-pregnancy (PP), pregnancy (P), and breastfeeding (BF) states using the HTG EdgeSeq platform. Differentially expressed (DE) miRNAs in pregnancy were identified with false discovery rate (FDR) < 0.1 (29 upregulated and 131 downregulated) by intersecting pairwise comparisons (P vs. PP and P vs. BF). Validated gene targets (2,733) were identified via miRWalk and modular enrichment analysis performed using Cytoscape/ClueGO. Enriched pathways (FDR<0.05) included Adaptive Immune Response, Hippo Signaling, Cellular Senescence, HSV-1 Infection, and two cancer-related pathways. Genes from pregnancy-enriched pathways overlapped with the known HIV-host interactome at the range of 37 to 88%. From this overlap, the Maximal Clique Centrally (MCC) score (cytoHubba) identified 47 unique hub genes acting as essential regulatory nodes of protein-protein interaction (PPI) network. These hub genes were further examined by their expression patterns predicted by DE miRNAs, and explored for their interactions with the HIV interactome, revealing connectivity with 18 HIV proteins - highest with Tat and gp120 - and impact on the HIV replication process. HLA-A was the most connected host gene, followed by BCL2L1, EIF2AK2, PTEN, and CYCS. These findings support the hypothesis that pregnancy-driven systemic miRNAs may shape HIV susceptibility by regulating hub genes with central role in viral evasion of host immunity. GRAPHIC
- Open Access
MICRORNAS AS REGULATORS OF DRUG METABOLISM AND TRANSPORT IN PREGNANT AND LACTATING WOMEN
Background: Physiological changes during pregnancy result in altered maternal drug metabolism that impacts efficacy and safety of therapeutics in pregnant women. Pregnancy induced hormonal, immunologic, or metabolic changes may also influence and alter drug disposition. Despite research efforts focused on pharmacokinetics of medications used in pregnant women in the past decade, knowledge gaps exist in understanding how pregnancy influences drug disposition and placental drug transporters. Moreover, there is a scarcity of research in understanding the safety and effectiveness of therapeutics in lactating women. This study aimed to determine the effect of pregnancy on levels of miRNAs regulating drug metabolizing enzymes and transporters (DMET). Methods: We utilized longitudinal serum specimens collected in 3-month intervals from 88 women who became pregnant during follow-up in a large prospective study of hormonal contraception and HIV acquisition in Uganda and Zimbabwe. We used the HTG EdgeSeq platform coupled with Illumina sequencing to obtain the global miRNA transcriptome in paired specimens collected before, during and after pregnancy. To identify differentially expressed (DE) miRNAs that distinguish pregnancy from pre-conception or breastfeeding we used mixed effect model accounting for multiple samples from the pregnancy event and controlling for fixed effects of batch, country, Nugent score category and sexually transmitted infections. To identify hormonally regulated miRNAs independently associated with Box-Cox-transformed levels of progesterone (P4), β-estradiol (E2), and sex-hormone binding protein (SHBG) we controlled in addition for age, pregnancy and breastfeeding P-values were corrected using the Benjamini-Hochberg false discovery rate (FDR). DMET-targeting miRNAs were identified using miRTarBase focusing on interactions verified by 3’-UTR luciferase reporter assay and overlapped with DE miRNAs with FDR < 0.05. Results: Of 140 DMET-targeting miRNAs among the 2079 miRNAs in the global peripheral blood transcriptome, 41 unique DMET-targeting miRNAs were found to be DE during pregnancy – 38 differentiating pregnancy from preconception and 9 differentiating pregnancy from breastfeeding. The 56 DMETs confirmed as targets of the DE miRNAs included 8 members of the ABC (ATP-binding cassette) transporter family, all abundantly expressed in the placenta, and 4 members of the cytochrome P450 Phase 1 enzyme family with major role in xenobiotics detoxification. The study also revealed a strong (FDR<0.05), predominantly positive association between specific DMET-targeting miRNAs and sex hormone-binding globulin (SHBG) levels, suggesting a miRNA-mediated downregulation of DMETs as SHBG levels rise during pregnancy. Conclusion: This research provides crucial insights into the molecular mechanisms underlying altered drug disposition in pregnant and lactating women, paving the way for improved therapeutic management and personalized medicine in these populations.
Open AccessMICRORNAS AS REGULATORS OF DRUG METABOLISM AND TRANSPORT IN PREGNANT AND LACTATING WOMEN
Background: Physiological changes during pregnancy result in altered maternal drug metabolism that impacts efficacy and safety of therapeutics in pregnant women. Pregnancy induced hormonal, immunologic, or metabolic changes may also influence and alter drug disposition. Despite research efforts focused on pharmacokinetics of medications used in pregnant women in the past decade, knowledge gaps exist in understanding how pregnancy influences drug disposition and placental drug transporters. Moreover, there is a scarcity of research in understanding the safety and effectiveness of therapeutics in lactating women. This study aimed to determine the effect of pregnancy on levels of miRNAs regulating drug metabolizing enzymes and transporters (DMET). Methods: We utilized longitudinal serum specimens collected in 3-month intervals from 88 women who became pregnant during follow-up in a large prospective study of hormonal contraception and HIV acquisition in Uganda and Zimbabwe. We used the HTG EdgeSeq platform coupled with Illumina sequencing to obtain the global miRNA transcriptome in paired specimens collected before, during and after pregnancy. To identify differentially expressed (DE) miRNAs that distinguish pregnancy from pre-conception or breastfeeding we used mixed effect model accounting for multiple samples from the pregnancy event and controlling for fixed effects of batch, country, Nugent score category and sexually transmitted infections. To identify hormonally regulated miRNAs independently associated with Box-Cox-transformed levels of progesterone (P4), β-estradiol (E2), and sex-hormone binding protein (SHBG) we controlled in addition for age, pregnancy and breastfeeding P-values were corrected using the Benjamini-Hochberg false discovery rate (FDR). DMET-targeting miRNAs were identified using miRTarBase focusing on interactions verified by 3’-UTR luciferase reporter assay and overlapped with DE miRNAs with FDR < 0.05. Results: Of 140 DMET-targeting miRNAs among the 2079 miRNAs in the global peripheral blood transcriptome, 41 unique DMET-targeting miRNAs were found to be DE during pregnancy – 38 differentiating pregnancy from preconception and 9 differentiating pregnancy from breastfeeding. The 56 DMETs confirmed as targets of the DE miRNAs included 8 members of the ABC (ATP-binding cassette) transporter family, all abundantly expressed in the placenta, and 4 members of the cytochrome P450 Phase 1 enzyme family with major role in xenobiotics detoxification. The study also revealed a strong (FDR<0.05), predominantly positive association between specific DMET-targeting miRNAs and sex hormone-binding globulin (SHBG) levels, suggesting a miRNA-mediated downregulation of DMETs as SHBG levels rise during pregnancy. Conclusion: This research provides crucial insights into the molecular mechanisms underlying altered drug disposition in pregnant and lactating women, paving the way for improved therapeutic management and personalized medicine in these populations.
- Open Access
Abnormal Vaginal Microbiota Associated with miRNA Targeting the HIV-Host Interactome
Understanding the molecular mechanisms underlying the ability of vaginal dysbiosis to alter the mucosal barrier to HIV acquisition is an essential step toward prevention. We hypothesized that micro(mi)-RNAs dysregulated by vaginal pathobiont bacteria epigenetically control host pathways exploited by the virus. The impact of these endogenous non-coding short RNAs on the anti-viral mucosal barrier function in the female reproductive tract is largely unknown. This study utilized cervicovaginal specimens collected during the luteal and follicular phase of the menstrual cycle along with data on age, race, ethnicity, education, and body mass index from 141 healthy reproductive-age women confirmed negative for sexually transmitted infections. Vaginal microbiota was classified by Nugent scoring. Shot-gun vaginal microbiome sequencing and metagenome taxonomic classification was performed on a subset of 21 women. Levels of miRNAs in exosomes isolated from cervicovaginal secretions were quantified using the EdgeSeq-NextGen global transcriptome platform. Differential expression (DE) was determined using R. Epigenetic target prediction was performed using MirTarBase. MiRNA profiles varied by both Nugent score categories (0-3 scores = normal, 4-6 = intermediate, and 7-10 = bacterial vaginosis, BV) and by metagenome classification. Higher microbiome diversity was associated with higher number of significantly dysregulated miRNAs (588 in BV compared to Nugent 0-3 versus 42 in Nugent 4-6 compared to Nugent 0-3, false discovery rate FDRG. vaginalis -dominated compared to L. crispatus -dominated metagenomes included 24 DE miRNAs (92% overlap with BV by Nugent score) and 112 validated target genes. BV-dysregulated miRNA mediated the immunosuppressive effects of BV on cytokine levels previously associated with HIV acquisition risk. The gene ontology predictions based on BV-dysregulated miRNAs identified enrichment for 445 downregulated and 50 upregulated genes previously validated as part of the HIV-host interactome. miRNAs mediation revealed a mechanism of suppressed immunity by BV predictive of HIV risk. In conclusion, miRNAs dysregulated by vaginal dysbiosis may facilitate immune imbalance and cellular pathways associated with HIV risk.
Open AccessAbnormal Vaginal Microbiota Associated with miRNA Targeting the HIV-Host Interactome
Understanding the molecular mechanisms underlying the ability of vaginal dysbiosis to alter the mucosal barrier to HIV acquisition is an essential step toward prevention. We hypothesized that micro(mi)-RNAs dysregulated by vaginal pathobiont bacteria epigenetically control host pathways exploited by the virus. The impact of these endogenous non-coding short RNAs on the anti-viral mucosal barrier function in the female reproductive tract is largely unknown. This study utilized cervicovaginal specimens collected during the luteal and follicular phase of the menstrual cycle along with data on age, race, ethnicity, education, and body mass index from 141 healthy reproductive-age women confirmed negative for sexually transmitted infections. Vaginal microbiota was classified by Nugent scoring. Shot-gun vaginal microbiome sequencing and metagenome taxonomic classification was performed on a subset of 21 women. Levels of miRNAs in exosomes isolated from cervicovaginal secretions were quantified using the EdgeSeq-NextGen global transcriptome platform. Differential expression (DE) was determined using R. Epigenetic target prediction was performed using MirTarBase. MiRNA profiles varied by both Nugent score categories (0-3 scores = normal, 4-6 = intermediate, and 7-10 = bacterial vaginosis, BV) and by metagenome classification. Higher microbiome diversity was associated with higher number of significantly dysregulated miRNAs (588 in BV compared to Nugent 0-3 versus 42 in Nugent 4-6 compared to Nugent 0-3, false discovery rate FDRG. vaginalis -dominated compared to L. crispatus -dominated metagenomes included 24 DE miRNAs (92% overlap with BV by Nugent score) and 112 validated target genes. BV-dysregulated miRNA mediated the immunosuppressive effects of BV on cytokine levels previously associated with HIV acquisition risk. The gene ontology predictions based on BV-dysregulated miRNAs identified enrichment for 445 downregulated and 50 upregulated genes previously validated as part of the HIV-host interactome. miRNAs mediation revealed a mechanism of suppressed immunity by BV predictive of HIV risk. In conclusion, miRNAs dysregulated by vaginal dysbiosis may facilitate immune imbalance and cellular pathways associated with HIV risk.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Estimated ovulatory years prior to menopause and postmenopausal endogenous hormone levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Estimated ovulatory years prior to menopause and postmenopausal endogenous hormone levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Estimated ovulatory years prior to menopause and postmenopausal endogenous hormone levels
Background Lifetime ovulatory years (LOY) is estimated by the difference between ages at menopause and menarche subtracting time for events interrupting ovulation. We tested whether LOY influences sex-hormone levels in postmenopausal women with at least one intact ovary not using hormones. Methods Estradiol, estrone, estrone sulfate, total testosterone, dehydroepiandrostendione sulfate (DHEAS), prolactin, and sex-hormone-binding globulin (SHBG) were measured in 1,976 postmenopausal women from the Nurses’ Health Study. Associations of age, body mass index (BMI), smoking, alcohol use, and other factors on hormones were assessed by t-tests and ANOVA. Linear regression was used to assess multivariable-adjusted associations between LOY and hormones and trends in hormone levels per 5-year increases in LOY were estimated. Results Women averaged 61.4 years old, 11.0 years since menopause, with BMI of 25.8 kg/m2. 13.6% had irregular cycles, 17.5% hysterectomy, 6.4% unilateral oophorectomy, and 13.8% were current smokers. Variables associated with one or more hormone levels were included as covariates. Each 5-year increase in LOY was significantly associated with a 5.2% increase in testosterone in women with BMI<25 kg/m2 and a 7.4% increase in testosterone and 7.3% increase in estradiol in women with above-average BMI. Conclusions This is the first study to show that greater LOY is associated with higher testosterone in postmenopausal women and higher estradiol in those with elevated BMI, suggesting accumulation of functioning stromal and thecal cells from repeated ovulations and peripheral conversion of testosterone. Impact A possible explanation for why greater LOY increases risk for breast, endometrial, and ovarian cancer is offered.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Estimated ovulatory years prior to menopause and postmenopausal endogenous hormone levels
Background Lifetime ovulatory years (LOY) is estimated by the difference between ages at menopause and menarche subtracting time for events interrupting ovulation. We tested whether LOY influences sex-hormone levels in postmenopausal women with at least one intact ovary not using hormones. Methods Estradiol, estrone, estrone sulfate, total testosterone, dehydroepiandrostendione sulfate (DHEAS), prolactin, and sex-hormone-binding globulin (SHBG) were measured in 1,976 postmenopausal women from the Nurses’ Health Study. Associations of age, body mass index (BMI), smoking, alcohol use, and other factors on hormones were assessed by t-tests and ANOVA. Linear regression was used to assess multivariable-adjusted associations between LOY and hormones and trends in hormone levels per 5-year increases in LOY were estimated. Results Women averaged 61.4 years old, 11.0 years since menopause, with BMI of 25.8 kg/m2. 13.6% had irregular cycles, 17.5% hysterectomy, 6.4% unilateral oophorectomy, and 13.8% were current smokers. Variables associated with one or more hormone levels were included as covariates. Each 5-year increase in LOY was significantly associated with a 5.2% increase in testosterone in women with BMI<25 kg/m2 and a 7.4% increase in testosterone and 7.3% increase in estradiol in women with above-average BMI. Conclusions This is the first study to show that greater LOY is associated with higher testosterone in postmenopausal women and higher estradiol in those with elevated BMI, suggesting accumulation of functioning stromal and thecal cells from repeated ovulations and peripheral conversion of testosterone. Impact A possible explanation for why greater LOY increases risk for breast, endometrial, and ovarian cancer is offered.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Estimated ovulatory years prior to menopause and postmenopausal endogenous hormone levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Estimated ovulatory years prior to menopause and postmenopausal endogenous hormone levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683